Agentix Corp.
AGTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AGTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AGTX
Agentix Corp. (AGTX) is a pre-revenue biotech company focused on developing treatments targeting the endocannabinoid system for indications including epilepsy, Type 2 diabetes, and acute kidney injury, with no approved products and substantial doubt about its ability to continue as a going concern.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for Agentix Corp..
Agentix Corp. (AGTX) is a pre-revenue biotech company focused on developing treatments targeting the endocannabinoid system for indications including epilepsy, Type 2 diabetes, and acute kidney injury, with no approved products and substantial doubt about its ability to continue as a going concern.
- Agentix Corp. is a pre-revenue biotech developing treatments targeting the endocannabinoid system for epilepsy, Type 2 diabetes, and acute kidney injury [sec · filed 2020-09-03].
- As of June 30, 2026, the company had cash of $38, an accumulated deficit of $7,124,838, negative working capital of $3,713,793, and a net loss of $117,674 for the three months then ended [sec_mda · as of 2026-08-10].
- The company has never submitted a New Drug Application (NDA) to the FDA and faces substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-08-10] [sec · filed 2020-09-03].
- Agentix Corp. has limited operations and no revenues, relying on equity or debt financing to fund its business plan [sec_mda · as of 2026-08-10] [sec · filed 2020-09-03].
What works
- The company has identified multiple programs targeting the endocannabinoid system for conditions such as epilepsy, Type 2 diabetes, and acute kidney injury, which are already in design, discovery, or pre-clinical testing with leading universities and research institutions [sec · filed 2020-09-03].
- The company is attempting to commence operations and generate sufficient revenue, indicating a continued effort to advance its business plan [sec_mda · as of 2026-08-10].
What to weigh
- As of June 30, 2026, the company had only $38 in cash, negative working capital of $3.7 million, and an accumulated deficit of $7.1 million, raising substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-08-10].
- The company has never submitted an NDA to the FDA, and clinical drug development is a lengthy, expensive process with uncertain outcomes; failure can occur at any stage [sec · filed 2020-09-03].
- The company has limited operating history and no revenues, and its ability to secure necessary financing through equity or debt is uncertain [sec_mda · as of 2026-08-10] [sec · filed 2020-09-03].
- Even if clinical trials are successful, additional trials are required before an NDA can be filed, and regulatory approval is not guaranteed [sec · filed 2020-09-03].
From the filings
Quoted directly from source documents.
The company had minimal cash and substantial going concern issues as of June 30, 2026.
“we had an accumulated deficit of $7,124,838, a net loss of $117,674, net cash used in operating activities of $26,372, negative working capital of $3,713,793, cash of $38, and total current liabilities of $3,713,831 as of June 30, 2026. These factors raise substantial doubt about our ability to continue as a going concern.”
SEC MD&A · August 10, 2026
The company has never submitted an NDA to the FDA.
“We have never submitted an NDA to the FDA or comparable applications to other regulatory authorities.”
SEC filings · September 3, 2020
The company's programs target the endocannabinoid system for several indications.
“endocannabinoid system for treatments ranging from epilepsy, Type 2 diabetes, and acute kidney Injury. These identified programs are already under development, ranging from design and discovery to pre-clinical and biological testing with leading universities and research institutions.”
SEC filings · September 3, 2020
The company has limited operations and no revenues.
“To date the Company has little operations or revenues and consequently has incurred recurring losses from operations.”
SEC filings · September 3, 2020
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — As of June 30, 2026, the company had only $38 cash and negative working capital, raising substantial doubt about its ability to continue [sec_mda · as of 2026-08-10].
- No regulatory approvals — The company has never submitted an NDA to the FDA, and clinical development is uncertain and expensive [sec · filed 2020-09-03].
- Dependence on financing — The company relies on equity or debt financing to fund operations, with no assurance of obtaining funds on reasonable terms [sec_mda · as of 2026-08-10].
- Pre-revenue stage — The company has no revenues and limited operations, with no anticipated revenue until its business plan is implemented [sec · filed 2020-09-03].
What to watch
- Ability to raise additional capital through equity or debt financing to fund operations and advance development programs [sec_mda · as of 2026-08-10].
- Progress of pre-clinical and clinical development programs targeting the endocannabinoid system for epilepsy, Type 2 diabetes, and acute kidney injury [sec · filed 2020-09-03].
- Any updates on regulatory submissions or interactions with the FDA or other authorities [sec · filed 2020-09-03].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Agentix Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Agentix Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
0.0 months
OCF -$26K · Net income -$118K
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Frequently asked questions
What is the AI investment thesis for Agentix Corp.?
Agentix Corp. (AGTX) is a pre-revenue biotech company focused on developing treatments targeting the endocannabinoid system for indications including epilepsy, Type 2 diabetes, and acute kidney injury, with no approved products and substantial doubt about its ability to continue as a going concern.
What is Agentix Corp.'s lead drug candidate?
Agentix Corp.'s most advanced tracked candidate is agtx-2003 (Preclinical) for obesity and non-alcoholic fatty liver disease (NAFLD).
Who is the CEO of Agentix Corp.?
Mr. Riazul Huda is the chief executive officer of Agentix Corp. (AGTX).
Where is Agentix Corp. headquartered?
Agentix Corp. (AGTX) is headquartered in Dana Point, CA, United States.
What therapeutic areas does Agentix Corp. focus on?
Agentix Corp. develops therapies across Metabolic, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.